Las Vegas:BioLab Holdings has rebranded as EmeraNova, expanding its focus from chronic wound care to include tissue restoration across various medical specialties, healing phases, and care settings.

According to BERNAMA News Agency, the company announced that the new corporate identity reflects its strategy to build a global platform that identifies and accelerates the integration of promising technologies into clinical practice. The name EmeraNova combines the words emerging (Emer) and new (Nova), symbolizing its pursuit of innovative technologies.

Jaime Leija, EmeraNova's President and CEO, stated that the company is committed to enhancing patient care by creating a more connected ecosystem and delivering innovations to clinicians and patients more swiftly. The company plans to expand into new care settings such as acute care and hospital outpatient departments, while continuing to serve outpatient and mobile wound clinics with its amniotic membrane products.

EmeraNova also aims to broaden its clinical applications into fields like surgery, sports medicine, vascular care, and aesthetics, with plans for international commercialization partnerships. The company's product offerings are organized into eight categories Assess and Differentiate, Diagnose, Debride, Control, Prepare, Restore and Regenerate, Reassess, and Remodel Tissue, seeking global partners to expedite market introduction of new technologies.

The company reported its clinical research covers several products, including four clinical trials and three published, peer-reviewed retrospective studies conducted in 2026. EmeraNova will unveil its new brand at the Symposium on Advanced Wound Care in Las Vegas from October 16 to 18.